FCGR3A and neoplasm: Overall, our data demonstrated that CNP has a great potential to be a robust biocompatible adjuvant for anti-tumor vaccine generation by mixing with tumor-derived oncogenic antigens of CTL and neoantigens, which is able to be simultaneously used with CD16 CAR-T for vaccine/CAR-T cells-based synergistic targeted anti-tumor immune therapy.